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Abstract 
This note explores the difference between QALYs gained and DALYs averted in 
estimates of health benefits from interventions, where DALYs are estimated using 
local life expectancy tables. I assume that disability weights in the DALYs 
framework correspond to quality adjustment weights in QALYs, that there is no 
age weighting and that both frameworks use the same discounting methodology. I 
find that for the same intervention, health benefit measured as a reduction in 
DALYs is always smaller than the same benefit measured as a gain in QALYs. 
The higher the age of deaths prevented by the intervention, and the lower the 
quality of life in the years of life gained, the bigger the difference between 
DALYs and QALYs. The difference is reduced when benefits are discounted. I 
show that the difference can lead to a different ranking in cost-effectiveness 
league tables based on DALYs averted compared to gains in QALYs. I conclude 
that the use of the DALY framework based on local life expectancy tables might 
be appropriate for estimating the total burden of disease, but leads to troubling 
results if used for cost-effectiveness analysis. The use of a fixed reference age 
would avoid those implications, but might not be a reasonable assumption for 
estimating the total burden of disease. 
 
Acknowledgments 
I am extremely grateful to Aki Tsuchiya and Alec Morton for stimulating the work 
presented in this paper. I am also grateful to John Howard, Gwyn Bevan, Julia Fox-
Rushby and participants of the Health Economists’ Study Group meeting at Brunel 
University for helpful discussion, Adam Oliver and Sarah Thomson for valuable 
comments and the Health Foundation for providing financial support. 
 
Author 
Mara Airoldi 
Operational Research Group, Department of Management 
London School of Economics and Political Science 
Houghton Street, London WC2A 2AE 
Tel: 020 7955 6234 - Email: m.airoldi@lse.ac.uk 
 2
Contents 
Page 
 
Abstract 2 
1 Background 4 
2 Measuring changes in mortality 7 
2.1 Without discounting (r=0) 7 
2.2 With discounting 10 
3 Measuring changes in morbidity 13 
4 Measuring changes in mortality and morbidity 15 
4.1 Without discounting 15 
4.2 With discounting 18 
5 Policy implications 20 
6 Conclusions 22 
References 24 
Appendix 25 
List of Tables and Figures 27 
 
 3
1 Background 
Quality-adjusted life years (QALYs) and Disability-adjusted life years (DALYs) are 
currently widely used in the economic evaluation of health. Although in their original 
formulations the methodological differences were important (Drummond et al., 2005, 
Gold et al., 1996, Gold et al., 2002, Fox-Rushby, 2002). In the light of subsequent 
developments, Morton has asked whether these differences are mainly semantic 
(Morton, 2007). Sassi analysed the difference between estimates of gains in QALYs and 
DALYs averted maintaining age weighting as in the original formulation of DALYs but 
using continuous discounting for both approaches (despite the fact that the original 
QALYs formula uses discrete time intervals) and assuming that the loss in quality of 
life associated with a disease in the QALY framework corresponded to the disability 
weight in the DALY one (and later relaxed this assumption) (Sassi, 2006). As Morton 
pointed out, however, the use of age weighting is currently considered discretionary 
among users of the DALY approach and it seems that once age weighting, differences 
in discounting and differences between loss in quality of life and disability weighting 
are set aside, the two frameworks do not differ substantially (Morton, 2007). In this 
technical note I explore a comment made by Aki Tsuchiya on Morton’s 2007 paper1. 
Tsuchiya pointed out that although developments have aligned the two approaches, as 
DALYs are usually estimated using residual life expectancy at the time of death, there is 
a difference between gains in QALYs and DALYs averted by the same health 
intervention. 
 
In this paper I explore how fundamental this difference is. The paper begins with an 
illustrative example and then considers three questions:  
1. In general how large is the difference in benefits when measured in DALYs and 
QALYs and what are its main determinants? 
2. What happens to the difference if we include discounting of future outcomes? 
3. Would the difference lead to contrasting ranking in league tables based on 
DALYs averted compared to QALYs gained? 
                                                 
1 Aki Tsuchiya discussed Morton’s paper at the Health Economists’ Study Group at the University of 
Birmingham in January 2007. 
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 The paper is not a general discussion of the most appropriate measure of health 
outcomes, nor an analysis of the limitation of these techniques. Rather, it analyses the 
two most commonly used measures of health outcomes to test whether there is a 
substantial difference between them after having set aside any dissimilarity in 
discounting method (which is stylistic), age weighting (which is currently discretionary) 
and divergences between the sets of weights representing quality of life in QALYs and 
disability weights in DALYs (which belong to the separate issue of measuring 
preferences). The intervention used in carrying out the comparison is a single year 
intervention, a context in which the use of measures such as DALYs with local life 
tables is recommended (Tan-Torres Edejer et al., 2003, Preston, 1993). 
 
Consider a person who lives until the age of 35 with a disease and then dies. We can 
represent her health over time using the QALY approach (Drummond et al., 2005, Gold 
et al., 1996) on a graph with time (age) on the horizontal axis and quality of life on the 
vertical axis, where quality of life varies between 0 (i.e. death) and 1 (i.e. full health) 
(see Figure 1). If we assume that the disease is associated with a quality of life lower 
than full health - say 0.8 - then the health profile of that person is h0 in the figure. The 
QALYs of this health profile are the number of years lived, multiplied by their quality 
and are graphically represented by the area below h0, which is 28 QALYs (35*0.8). 
Imagine now an intervention that could save her from death and extend her life by 30 
years, but would leaver her with a more severe disability with a quality of life of 0.5. 
The new health profile can be drawn and is represented by h1 in the figure, which 
corresponds to 43 QALYs (35*0.8+30*.5). The health outcome of the intervention can 
then be thought as the difference between the QALYs of h1 and those of h0; that is, 15 or 
the years of life gained weighted by their quality (30*0.5). 
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Figure 1. QALYs gained vs. DALYs averted. A numerical example. 
 
On the same graph we could also represent the DALYs (Murray, 1996) associated with 
the two health profiles and evaluate the intervention in terms of reduction in the burden 
of disease. Although the DALY approach is a population-based method, in this paper 
we consider an individual as a special case of a population or as a summand in the 
estimate of the health outcome at the population level (Gold et al., 2002, Morton, 2007, 
Sassi, 2006). The burden of disease is the difference between an ideal health profile, 
which typically corresponds to living in full health for the rest of one’s life, and the 
actual health profile. In studies that evaluate a one-year intervention, the use of local life 
tables and of residual life expectancy at the age of death to quantify the ‘rest of one’s 
life’ is recommended (Murray, 1996, Preston, 1993). In the example of Figure 1, the 
ideal health profile in the absence of the intervention is R0, that is living in full health 
for the residual life expectancy at age 35 in the population (45 years according to recent 
life tables for England (GAD, 2006); that is, until the age of 80). The burden of disease 
associated with health profile h0 is then 52 DALYs (35*(1-0.8)+45). The selected 
intervention, extending the person’s life until age 65, shifts the ideal health profile to R1, 
that is living in full health for the residual life expectancy at age 65 in the population 
(18 years according to the life table used above, that is until 83 years old); the burden of 
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h1 is 40 (35*(1-0.8)+30*(1-0.5)+18) and the DALYs averted through the intervention 
are therefore 12, which is lower than the QALYs gained which we estimated to be 15. 
 
I begin the analysis with a simple model of mortality and a life-extending intervention, 
initially without discounting and then including a positive discount rate r. I then briefly 
consider a model with changes in morbidity only and move to the more complete model 
of an intervention that affects both morbidity and mortality. 
 
2 Measuring changes in mortality  
2.1 Without discounting (r=0) 
Consider an individual who will live in full health and die at age x; now imagine an 
intervention that could save her from death and extend her life by k years, maintaining 
her in full health. The gains in QALYs associated with the intervention are graphically 
represented by area K in Figure 2; that is, k as shown by (1). The same health outcome 
measured as a reduction in DALYs is the difference between area K and area G in 
Figure 2 and formulated in (2). Graphically it is easy to see that the use of QALYs or 
DALYs gives a different measure of the health benefit from the intervention and that 
this difference is area ,G which is measured by (3). G is the difference between the age 
a person is expected to die if she is (x+k) years old and the age she is expected to die 
when she is x years old. As we discuss in the Appendix, G≥0 always. 
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Figure 2. Health profiles with change in mortality only and no discounting. 
 
(1) ; kxkxQALYs =−+=Δ )(
(2) ; )()( kxLxLDALYs +−=Δ
where L(x) is the residual life expectancy of a person aged x in the local general 
population. 
(3) G(x, k) = ;  )()( kxLxLkDALYsQALYs ++−=Δ−Δ
 
The discrepancy, G, can be estimated numerically by varying parameters x and k. For 
L(·) I used the life expectancy data for the male English population (GAD, 2006), varied 
the age of death in the absence of the intervention, x, between 0 and 100, and varied the 
years of life added by the health intervention, k, between 1 and the residual life 
expectancy at age x, assuming that an intervention able to extend life beyond the life 
expectancy in the population is not feasible, on average. Using life tables for England, 
where infant mortality is relatively low, we also expect G(x, k) ≤ k (see discussion in the 
Appendix). 
 
Results for a small selection of k values are shown in Figure 3, where the x-axis is the 
age of death without the intervention. As expected, 0 ≤ G(x, k) ≤ k. The discontinuity 
between age 0 and 1 is due to the massive impact of mortality rates between age 0 and 1 
on the calculation of residual life expectancy. 
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Figure 3. Estimates of G for a small selection of k values, no discounting. The age of death without the 
intervention (x) is reported on the x-axis. The age of death with the intervention is x+k. 
 
The relative underestimate of health benefits as measured in DALYs compared to 
QALYs can be expressed by a ratio, α, as in (4). The smaller the difference, the closer α 
will be to 1. The bigger the difference, the smaller the value of α. 
 
k
kxLxL
QALYs
DALYs )()( +−=Δ
Δ=α(4) ;   0 ≤ α ≤ 1 
 
 
Figure 4 reports the results for α, where each line represents a different k (from 1 to 76, 
i.e. the maximum length of life added by an intervention is equal to life expectancy at 
birth) and where higher lines correspond to smaller k (with the exception of deaths 
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avoided at birth). Figure 4 shows that α decreases both with x and k, with discontinuities 
for death at birth or in the first year of life. 
Alpha 
values 
for k=1
Alpha 
values 
for k=30
Alpha 
values 
for k=76
 
Figure 4. Estimates of alpha, no discounting.  
α is the ratio between DALYs averted and QALYs gained by virtue of the intervention and is on the 
vertical axis. Each line corresponds to a different value of k, the years of life added by the intervention. 
 
2.2 With discounting 
Discounting affects the results in two ways. First, it reduces the life expectancy of 
young people proportionally more than that of older people (because a larger proportion 
of their residual life expectancy is in a more distant future). Secondly, the more the life 
years gained (k), the later the death under the intervention scenario, i.e. the later its 
burden will manifest and the smaller its discounted value (Figure 5). 
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Figure 5. Health profiles with change in mortality only and with discounting. 
 
For notational simplicity, and without any loss of generality, we may assume that in the 
absence of the intervention, the individual affected by the disease will die in the current 
year at age x, whereas under the intervention scenario he will die k years from now at 
age x+ k. 
 
I estimated the gains in DALYs and reduction in DALYs varying the parameters k and x 
as before and I used exponential discounting for both DALYs and QALYs. The ratio 
between the two measures with exponential discounting is given in (5). Note that this is 
a generalisation and corresponds to (4) for r=0. 
∫
∫∫
−
++
−− −
=Δ
Δ= k
rt
kxLk
k
rt
xL
rt
dte
dtedte
QALYs
DALYs
0
)()(
0α(5)  
 
The results are shown in Figure 6, with a discount rate of 3.5% (the rate recommended 
for economic evaluations in the United Kingdom (NICE, 2006)). As expected, 
discounting reduces the difference between the two measures; that is, for any x and k, α 
is now closer to 1 (in terms of Figure 5 this is the ratio between area K-G and area K: 
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discounting reduces G proportionally more than K, and hence increases the ratio of K-G 
to K).  
 
Figure 6. Estimates of alpha discounting at 3.5%. 
 
Table 1 gives values of α for different values of x and k, with and without discounting. 
The table shows that, in general, the difference between DALYs averted and QALYs 
gained: 
• increases (i.e. α becomes smaller) with the age of death without the 
intervention; 
• increases with the length of life added by the intervention (k); and 
• decreases (i.e. α is closer to 1) if future outcomes are discounted. 
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Table 1. Values of α for a selection of ages at death without the intervention (x), length of life added by 
the intervention (k) and discounting. 
No discounting (r=0) With discounting (r=3.5%) x 
k=1 k=10 k=30 k=1 k=10 k=30 
5 .99 .99 .97 .999 .999 .996 
30 .96 .95 .91 .99 .99 .975 
65 .74 .67 n/a .85 .80 n/a 
90 .25 n/a n/a .34 n/a n/a 
 
3 Measuring changes in morbidity 
The quality of life of an individual is denoted by λ∈[0,1] where λ=0 corresponds to 
death and λ=1 to full health and we assume in the DALY framework the corresponding 
disability weight is 1-λ.  
 
Consider an individual of age x who will live for k years with a quality of life λ0∈(0,1) 
and die at age x+k. Figure 7 illustrates his health profiles for an intervention that 
improves his quality of life to λ1∈(λ0,1)> λ0 but has no effect on his life expectancy. 
Both the gain in QALYs and the reduction in DALYs corresponds to area Q; that is, 
there is no difference between the two measures as also shown in (6) and (7). 
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Figure 7. Health profiles with change in morbidity only, no discounting. 
 
)(* 01 λλ −=Δ kQALYs(6)   
)(*)(*)1()(*)1( 0110 λλλλ −=+−−−++−=Δ kkxLkkxLkDALYs(7) 
 
 
Including a positive discount rate will have the same effect on the two measures, which 
will therefore remain the same. 
 
The next section considers the ratio α for interventions that have an impact on both life 
expectancy and morbidity. 
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4 Measuring changes in mortality and morbidity 
4.1 Without discounting 
Figure 8 illustrates the health profile of a person who will live until age x with a quality 
of life of λ0 and an intervention that could extend her life by k years, during which her 
quality of life will be λ1<λ0. The gains in QALYs graphically correspond to area A in  
Figure 8 and are equal to (8). The same health outcome measured with the DALYs 
approach corresponds to the difference between area A and area G in the figure as 
shown by (9).  
 
A
Y G
x x+L(x)
x+k+L(x+k)
x+k
QoL
1
0
λ0
λ1
D
B
age
 
Figure 8. Health profiles with changes in mortality and morbidity. No discounting. 
 
1*λkQALYs =Δ(8) ; 
)1(*)()( 1λ−−+−=Δ kkxLxLDALYs(9) ; 
(10) . )()( xLkxLkDALYsQALYs −++=Δ−Δ
 
As in our initial model of changes in mortality only, the difference between the two 
measures is due to the increase in life expectancy that accrues with age (area G in the 
Figure) as shown in (10), which is identical to (3). This is as expected because, as 
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shown in the previous section, changes in morbidity are identically measured in the two 
frameworks, once we assume identical evaluation of health states, same discounting 
technique and no age-weighting. But this makes it more complex to estimate the effect 
on α, the ratio between the two measures. 
 
Let α’ denote the ratio between the reduction in DALYs and the gain in QALYs in this 
model (11). The difference between the ratio α’ and ratio α in the model with mortality 
only (5) is given in (12). By inspecting equation (12) it is easy to see that it is positive 
for any λ1∈ (0,1) and that the higher the quality of life during the years of life gained, 
λ1, the closer the two ratios. (Note that the model analysed here is a generalisation of the 
model with mortality only and reduces to that model when λ1=1). 
 
1
1
*
)1(*)()(' λ
λα
k
kkxLxL
QALYs
DALYs −−+−=Δ
Δ=(11) ; 
1
1
*
)]()([*)1(' λ
λαα
k
kxLxLk ++−−=−(12) . 
 
I estimated α’, varying parameters x, k as before and λ1 between 0.1 and 1. Results for 
k=1 and k=30 are reported below. Note that these graphs are different from the previous 
ones and the series now correspond to different values of λ1. In both Figure 9 and  
Figure 10 the highest line represents λ1=1 and corresponds, respectively, to the series 
k=1 and k=30 in Figure 4. It can be easily seen that for λ1 equal to 1, α’ equals α. As 
expected, the higher the disability, the lower α’. 
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λ=0.1
λ=1
 
Figure 9. Estimates of α, varying λ. Case k=1, r=0. 
 
 
One troubling characteristic of the DALY methodology is that for deaths avoided in a 
relatively older age group, the reduction in DALYs becomes negative. This happens 
when the years added to life, adjusted for their quality, are less then the gains in life 
expectancy associated with surviving until an older age (in Figure 8, this means that 
area G is bigger than area A). 
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Figure 10. Estimates of α, varying λ. Case k=30, r=0. 
 
 
4.2 With discounting 
Using exponential discounting at 3.5% as before, I estimated the gains in QALYs and 
the DALYs averted through the intervention, varying parameters x, k and λ. The 
graphical representation of the discounted health profiles is given in Figure 11 and the 
ratio α in (13).  
∫
∫∫
−
++
−− −
=Δ
Δ= k
rt
kxLk
xL
rt
k
rt
dte
dtedte
QALYs
DALYs
0
1
)(
)(0
*
*
'
λ
λ
α  (13) 
 
Sample results for k=1 and k=30 are reported in Figure 11 and Figure 12. Results are 
qualitatively similar to the case without discounting, but the difference between the two 
measures is now lower (α is closer to 1). This is as we expect, because discounting 
affects G more than A. 
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Figure 11. Estimates of α, varying λ. Case k=1, r=3.5%. 
 
Figure 12. Estimates of α, varying λ. Case k=30, r=3.5%. 
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5 Policy implications 
The existence of a systematic difference between health benefits measured as gains in 
QALYs or DALYs averted for the same intervention might be considered a mere 
theoretical issue if it made no difference to policy decisions. I will discuss the policy 
implications of this systematic difference using the following example. 
 
Consider a decision maker who can fund treatment for one and only one of the 
following people: 
- a 65 year old man who has entered the end stage of an illness and is assumed to 
die today.  
- a 45 year old man who has entered the end stage of an illness and is assumed to 
die today. 
The person receiving the treatment will live for an extra year with quality of life valued 
at 0.1 on a 0 to 1 scale where the quality of life associated with being dead is 0 and that 
associated with perfect health is 1. Let us assume that the decision maker wants to 
maximise the health benefit, measured as gains in QALYs or reduction in DALYs. 
 
If the decision maker measures the health benefit with a QALY metric, funding any of 
the two interventions would lead to a gain of 0.1 QALYs and the decision maker might 
set up a lottery to determine who will receive the intervention or invoke further decision 
criteria, e.g. to favour younger over older patients on a fair-innings argument. On the 
other hand, if the decision maker measures the health benefit using a DALY metric, 
funding the first intervention would lead to an increase in the burden of disease of 0.16 
DALYs, but funding the second intervention to a slight reduction in the burden of 
disease of 0.02 DALYs and would then offer the treatment to the 45 year old man. In 
fact, s/he would not provide the intervention to the 65 year old man even if resources 
were available to fund it, because his death today is associated with a lower burden of 
disease than his death in a year’s time, which is at variance with the original assumption 
that a quality of life of 0.1 is better than death. 
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The size of the QALY gain depends solely on the years of life gained, that is one year in 
both cases, and the quality of life during those years, that is 0.1 in both cases. In this 
sense it endorses an egalitarian judgment, that is, QALYs are equal, no matter who 
receives them. This is a controversial issue in the literature and some argue that a 
QALY gained by a younger person should be valued more than a QALY gained by an 
older one (Williams, 1997). Arguments in favour of age weighting have not yet been 
successful in shifting the standard QALY framework. On the contrary, the debate has 
moved the DALY framework somewhat away from its original formulation which 
advocated the use of an age-weighting function (Anand and Hanson, 1997, Tan-Torres 
Edejer et al., 2003). The DALY framework, however, still systematically favours 
younger over older patients on the basis of a statistical artefact, as shown in this paper. 
In the example discussed in this section, for instance, the decision maker would favour 
the 45 year old not because she explicitly uses an age-weighting function, nor because 
the younger patient has a greater ability to benefit. Being alive for an additional year 
shifts the reference age used in the DALY calculation relatively more for the older 
patient than for the younger one. Hence, for an identical gain in health, the burden of 
disease remaining would be higher after treating the old patient than the young one and 
the latter will be favoured.  
 
Similarly, this proportionally different shift in the reference age between younger and 
older patients determines the internal inconsistency mentioned above. That is, although 
a state of poor health is valued more than death, an intervention leading to immediate 
death might be preferred to one leading to poor health. 
 
These two troubling implications would disappear if a fixed reference age were used. In 
this case the DALYs averted by an intervention that would prolong life from age x to 
age x+k with quality of life λ1∈ (0,1) would be equal to the QALY gained (having set 
aside: the use of age-weighting in DALYs, the difference between quality of life and 
disability weights and the different discounting techniques). Equation (14) shows the 
DALYs averted assuming a fixed reference age of T years, which corresponds to gains 
in QALYs (equation (8)). 
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The choice of a reference age higher than the oldest person in the population would be 
sufficient to avoid the implications discussed above.  
 
 
6 Conclusions 
This note has explored the difference between estimating the benefits of a health 
intervention in DALYs averted and in QALYs gained. I assumed that the health 
intervention adds k years of life with quality of life equal to λ1; I also assumed that 
disability weights to estimate DALYs correspond to quality adjustment weights from 
the QALY framework. I did not use any age weighting and I used local period life 
tables in the DALY calculation as recommended for evaluating the benefits of a one-
year intervention that does not affect age-specific mortality rates in the population 
(Murray, 1996, Preston, 1993). I found that, first, there is a systematic difference in the 
benefits from an intervention estimated as DALYs averted versus QALYs gained. 
DALYs averted are always less than QALYs gained and the higher the age of avoided 
deaths and the lower the quality of life in the years of life gained, the bigger the 
difference. Second, discounting reduces the difference between gains in QALYs and 
DALYs averted. Third, the ranking of interventions according to DALYs averted can be 
different from the ranking of the same interventions measured by gains in QALYs. For 
instance, for deaths avoided in a relatively older age group, the reduction in DALYs can 
be negative; that is, the intervention increases the burden of disease, whereas the gains 
in QALYs are always positive. 
 
The difference between gains in QALYs and DALYs averted, G(x, k), is determined by 
the change in residual life expectancy at different ages, which affects the DALY 
calculation but not the QALY one, as shown in Figure 2, Figure 5,  
Figure 8 and in the Appendix. There is an historical justification for this. QALYs were 
originally developed to estimate the benefits of interventions for the average patient. 
The gain in life years resulting from the intervention, weighted for quality, is the natural 
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way to measure them and they are unaffected by considerations of the average length 
and quality of life of people that do not need the intervention. On the contrary, DALYs 
were originally developed to measure the current burden of disease for a population 
where the burden is the gap between the health of a specific, real population and an 
ideal, healthier population. The natural way to measure the burden associated with 
premature mortality at age x in the actual population is the residual life expectancy of a 
person who is x years old in the ideal population and will live another L(x) years. The 
use of the DALY framework to estimate the change in the burden of disease associated 
with an intervention is a subsequent development (Murray and Lopez, 1994). As this 
note shows, however, the use of residual life expectancy generates troubling results 
when the DALYs framework is used to estimate the health benefits of an intervention. 
The use of a fixed reference age would remove these differences in measuring the 
benefits of an intervention, but might not be a reasonable assumption for the estimate of 
the current burden of disease. 
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Appendix 
In this appendix I discuss when 0 ≤ G(x, k) ≤ k. I do this in two steps. First, I discuss the 
shape of the residual life expectancy L(x), identifying the conditions under which its 
first derivative lies between -1 and 0. Then, I will show that G(x ,k) is always positive 
and discuss when G(x, k) ≤ k. 
 
Let us define the following three functions (Lindsey, 2004, Keyfitz, 1968):  
(1) the survivor function, S(x), that is the probability of living until age x: 
(15) ; ∫∞=−=>=
x
dttfxFxTxS )()(1]Pr[)(
where F(x) is the cumulative distribution and f(x) is the corresponding density 
function; 
(2) the mortality rate, λ(x), that is the instantaneous probability that death will occur 
at age x: 
)(
)()(
xS
xfx =λ(16) ; 
 
(3) the residual life expectancy, L(x), that is the average prospective lifetime of an 
individual aged x: 
)(
)(
)(
xS
dttS
xL x
∫∞
=(17) ; 
 
Differentiating L(x) with respect to x: 
)()(1
)())((
2
2
xLx
S
dttSxfS
dx
dL x ⋅+−=
−−−
=
∫
∞
λ(18) ; 
 
It can be easily seen that dL/dx≥-1 always, because both λ(x) and L(x) are non negative; 
and dL/dx≤0 if and only if λ(x)·L(x)≤1, that is residual life expectancy is a decreasing 
function in correspondence of ages x where 
)(
1)(
x
xL λ≤ .  
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 Empirical analysis of life tables shows that L(x) may increase during early years of life, 
when there is a high risk of infant mortality. In developed countries, where the life 
expectancy at birth is above 70 years, this usually happens only for the first year of life 
or even just for the first few months, and L(x) is a decreasing function of age x thereafter 
(Goldman and Lord, 1986, Coale and Demeny, 1983, Shrestha, 2005).  
 
Let us now discuss when 0 ≤ G(x, k) ≤ k. We recall from (3) that G(x, k) = 
. )()( kxLxLk ++−
We can re-write G(x, k) as  
⎥⎦
⎤⎢⎣
⎡ −++⋅
k
xLkxLk )()(1G(x ,k) = = 
  
⎥⎦
⎤⎢⎣
⎡ −+++−+−−++−+−++⋅
k
xLxL
k
kxLkxL
k
kxLkxLk )()1(...)2()1()1()(1 . = 
The years gained with the intervention, k, are non-negative. As we discussed above, the 
first derivative of L(x) is greater than -1 for any x, hence the term in square brackets is 
non negative, that is G(x, k)≥ 0 always. Similarly, for values of x where the first 
derivative dL/dx ≤ 0, that is when λ(x)·L(x)≤1, the term in square brackets is less than 
one, hence G(x, k)≤ k. 
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